1. Case report: Durable response to afatinib in a patient with lung cancer harboring two uncommon mutations of EGFR and a KRAS mutation
   Junko Tanizaki et al, 2016, Lung Cancer CrossRef
2. Functional coding/non-coding variants in EGFR, ROS1 and ALK genes and their role in liquid biopsy as a personalized therapy
   Mahmut Cerkez Ergoren et al, 2020, Critical Reviews in Oncology/Hematology CrossRef
3. Efficacy of EGFR tyrosine kinase inhibitors in non-small cell lung cancer patients harboring different types of EGFR mutations: A retrospective analysis
   Hua-li Liu et al, 2017, Current Medical Science CrossRef
4. Heterogeneity of resistance mutations detectable by next-generation sequencing in TKI-treated lung adenocarcinoma
   Deborah A. Belchis et al, 2016, Oncotarget CrossRef
5. Investigating mutation-specific biological activities of small molecules using quantitative structure-activity relationship for epidermal growth factor receptor in cancer
   P. Anoosha et al, 2017, Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis CrossRef
6. Next-Generation Sequencing
   Snehal B. Patel et al, 2017, The Journal of Molecular Diagnostics CrossRef
7. Synchronous occurrence of squamous-cell carcinoma “transformation” and EGFR exon 20 S768I mutation as a novel mechanism of resistance in EGFR-mutated lung adenocarcinoma
   Lucia Longo et al, 2017, Lung Cancer CrossRef
8. Current management of uncommon EGFR mutations in non-small cell lung cancer
   Jonathan Q. Trinh et al, 2024, Current Problems in Cancer CrossRef